| | |
| Clinical data | |
|---|---|
| Other names | GR-3027; 3α-Ethynyl-3β-hydroxyandrostan-17E-one oxime |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C21H31NO2 |
| Molar mass | 329.484 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Golexanolone, also known by the developmental code name GR-3027, is a neurosteroid medication which is under development for the treatment of hypersomnia and hepatic encephalopathy. [1] [2] [3] [4] It acts as a negative allosteric modulator of the GABAA receptor. [1] [2] The medication selectively antagonizes the stimulatory actions of inhibitory neurosteroids like allopregnanolone and tetrahydrodeoxycorticosterone (THDOC) at the GABAA receptor, while not affecting the activation of the GABAA receptor by γ-aminobutyric acid (GABA). [2]